Journal of Multidisciplinary Applied Natural Science
##plugins.themes.gdThemes.journalSlogan##
Scopus CiteScore 2024
4.8
Calculated on 05 May, 2025
SJR 2024
0.31
Powered by scimagojr.com
##plugins.themes.gdThemes.journalSlogan##
4.8
Calculated on 05 May, 2025
0.31
Powered by scimagojr.com
https://doi.org/10.47352/jmans.2774-3047.340
Nasr Allahloubi
Lydia Faragallah Lamie Soliman
Hesham Abd-Elkader El-Hossieny
Abeer Ahmad Bahnassy
Ahmed Mostafa Mahmoud
Total neoadjuvant therapy (TNT) is becoming increasingly popular as a systemic treatment for locally advanced rectal cancer (LARC), serving as an alternative to standard neoadjuvant concurrent chemoradiotherapy (CCRT). This study compared TNT versus neoadjuvant CCRT in cases of LARC. This phase II randomized controlled study included 30 patients with LARC (stages T2N1-2, T3, T4), who were randomized into two groups. The TNT group (n=15) received a long-course CCRTH followed by 2 cycles of consolidation chemotherapy with XELOX before surgery. The CRT group (n=15) received a long course of CCRTH followed by surgery. The cumulative dose of radiation in the current chemoradiation therapy was 50.4 Gy. All patients underwent total mesorectal excision (TME). The primary outcome measures were pathologic complete response (pCR) rate and 3-year event-free survival (EFS). The two groups were compared using Pearson’s Chi-square test, Fisher’s exact test, t-test, or the Mann-Whitney test. Survival analysis was performed using the Kaplan-Meier method, with group comparisons made using the log-rank test. A p-value < 0.05 was considered significant. Five patients in the TNT Group had a pCR compared to none in the CRT group (p=0.042). Moreover, 8 of the remaining 10 patients showed downstaging. In the CRT group, downstaging was observed in 6 patients (40%). Lymph nodes were positive in 3 patients of the TNT group compared to 10 of the CRT group (p=0.010). At 3 years, the overall survival of the TNT group was 86.2% compared to 57% in the CRT group (p=0.034). The event-free survival was 73.3% and 26.7% in the TNT and CRT Groups, respectively (p=0.021). CCRTH toxicity profile was comparable in both groups, mainly in the form of diarrhea, bleeding per rectum, peripheral neuropathy, cystitis, and neutropenia. In patients with LARC, TNT incorporating consolidation chemotherapy after long-course CCRTH before TME is superior to chemoradiation alone. TNT is associated with a higher complete pathological response, reduced local and distant metastases, and enhanced overall and disease-free survival, with a comparable toxicity profile to CRT alone.
[1] F. Bray, M. Laversanne, H. Sung, and J. Ferlay. (2024). "Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries". CA: A Cancer Journal for Clinicians. 74 (3): 229-263. 10.3322/caac.21834.
DOI: https://doi.org/10.3322/caac.21834[2] S. A. Alessy, E. Morgan, A. S. Al-Zahrani, and M. Zahwe. (2025). "Burden of five major types of gastrointestinal cancer in the Eastern Mediterranean Region". BMJ Open Gastroenterology. 12 (1): e001577. 10.1136/bmjgast-2024-001577.
DOI: https://doi.org/10.1136/bmjgast-2024-001577[3] A. J. Scott, E. B. Kennedy, J. Berlin, and G. Brown. (2024). "Management of locally advanced rectal cancer: ASCO guideline". Journal of Clinical Oncology. 42 (28): 3355-3375. 10.1200/JCO.24.01160.
DOI: https://doi.org/10.1200/JCO.24.01160[4] H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, and I. Soerjomataram. (2021). "Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries". CA: A Cancer Journal for Clinicians. 71 (3): 209-249. 10.3322/caac.21660.
DOI: https://doi.org/10.3322/caac.21660[5] M. Duzova, H. Basaran, G. Inan, and O. V. Gul. (2021). "Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Outcomes of survival, toxicity, sphincter preservation, and prognostic factors". Transplant Immunology. 69 101489. 10.1016/j.trim.2021.101489.
DOI: https://doi.org/10.1016/j.trim.2021.101489[6] R. Sauer, T. Liersch, S. Merkel, and R. Fietkau. (2012). "Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years". Journal of Clinical Oncology. 30 (16): 1926-1933. 10.1200/JCO.2011.40.1836.
DOI: https://doi.org/10.1200/JCO.2011.40.1836[7] T. Conroy, J. F. Bosset, P. L. Etienne, and E. Rio. (2021). "Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): A multicentre, randomised, open-label, phase 3 trial". The Lancet Oncology. 22 (5): 702-715.
[8] R. R. Bahadoer, E. A. Dijkstra, B. van Etten, and C. A. M. Marijnen. (2021). "Short-course radiotherapy followed by chemotherapy before total mesorectal excision versus preoperative chemoradiotherapy, surgery, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): A randomised, open-label, phase 3 trial". The Lancet Oncology. 22 (1): 29-42.
[9] R. Ryan, D. Gibbons, J. M. P. Hyland, and D. Treanor. (2005). "Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer". Histopathology. 47 (2): 141-146. 10.1111/j.1365-2559.2005.02176.x.
DOI: https://doi.org/10.1111/j.1365-2559.2005.02176.x[10] C. Fernández-Martos, C. Pericay, J. Aparicio, and A. Salud. (2010). "Phase II randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant CAPOX compared with induction CAPOX followed by chemoradiotherapy and surgery in MRI-defined locally advanced rectal cancer". Journal of Clinical Oncology. 28 (5): 859-865. 10.1200/JCO.2009.25.8541.
DOI: https://doi.org/10.1200/JCO.2009.25.8541[11] A. Habr-Gama, R. O. Perez, I. Proscurshim, and R. M. Nunes dos Santos. (2008). "Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: Does delayed surgery have an impact on outcome?". International Journal of Radiation Oncology, Biology, Physics. 71 (4): 1181-1188. 10.1016/j.ijrobp.2007.11.035.
DOI: https://doi.org/10.1016/j.ijrobp.2007.11.035[12] E. Fokas, A. Schlenska-Lange, B. Polat, and G. Klautke. (2022). "Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: Long-term results of the CAO/ARO/AIO-12 randomized clinical trial". JAMA Oncology. 8 (1): e215445.
[13] F. Petrelli, F. Trevisan, M. Cabiddu, and G. Sgroi. (2020). "Total neoadjuvant therapy in rectal cancer: A systematic review and meta-analysis of treatment outcomes". Annals of Surgery. 271 (3): 440-448. 10.1097/SLA.0000000000003471.
DOI: https://doi.org/10.1097/SLA.0000000000003471[14] E. Fokas, M. Allgäuer, B. Polat, and G. Klautke. (2019). "Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer (CAO/ARO/AIO-12)". Journal of Clinical Oncology. 37 (34): 3212-3222. 10.1200/JCO.19.00308.
DOI: https://doi.org/10.1200/JCO.19.00308[15] A. J. Franke, H. Parekh, J. S. Starr, and S. A. Tan. (2018). "Total neoadjuvant therapy: A shifting paradigm in locally advanced rectal cancer management". Clinical Colorectal Cancer. 17 (1): 1-12. 10.1016/j.clcc.2017.06.008.
DOI: https://doi.org/10.1016/j.clcc.2017.06.008[16] S. Tohme, R. L. Simmons, and A. Tsung. (2017). "Surgery for cancer: A trigger for metastases". Cancer Research. 77 (7): 1548-1552. 10.1158/0008-5472.CAN-16-1536.
DOI: https://doi.org/10.1158/0008-5472.CAN-16-1536[17] C. W. Kim, I. Y. Kim, and S. H. Lee. (2017). "Consolidation chemotherapy for locally advanced mid- or low rectal cancer after neoadjuvant concurrent chemoradiotherapy: A multicenter randomized controlled trial (KONCLUDE)". Journal of Clinical Oncology. 35 (4 Suppl): TPS813. 10.1200/JCO.2017.35.4_suppl.TPS813.
DOI: https://doi.org/10.1200/JCO.2017.35.4_suppl.TPS813[18] M. Awawda, T. Taha, S. Salman, and S. Billan. (2022). "The evolving treatment paradigm of locally advanced rectal cancer: A narrative review". Journal of Gastrointestinal Oncology. 13 (4): 2033-2047. 10.21037/jgo-22-13.
DOI: https://doi.org/10.21037/jgo-22-13[19] M. Gabbani, C. Giorgi, G. Napoli, and U. Tebano. (2022). "Outcomes of locally advanced rectal cancer patients treated with total neoadjuvant treatment: A meta-analysis of randomized controlled trials". Clinical Colorectal Cancer. 21 (4): 297-308. 10.1016/j.clcc.2022.07.005.
DOI: https://doi.org/10.1016/j.clcc.2022.07.005[20] S. Y. Kim, J. Joo, T. W. Kim, and Y. S. Hong. (2018). "A randomized phase II trial of consolidation chemotherapy after preoperative chemoradiation therapy versus chemoradiation therapy alone for locally advanced rectal cancer (KCSG CO 14-03)". International Journal of Radiation Oncology, Biology, Physics. 101 (4): 889-899. 10.1016/j.ijrobp.2018.04.013.
DOI: https://doi.org/10.1016/j.ijrobp.2018.04.013[21] J. Jin, Y. Tang, C. Hu, and Y. Cai. (2021). "A multicenter randomized phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR): Final report". Journal of Clinical Oncology. 39 (15 Suppl): 3510. 10.1200/JCO.2021.39.15_suppl.3510.
DOI: https://doi.org/10.1200/JCO.2021.39.15_suppl.3510[22] J. Moore, T. Price, S. Carruthers, and S. Selva-Nayagam. (2017). "Prospective randomized trial of neoadjuvant chemotherapy during the wait period following preoperative chemoradiotherapy for rectal cancer: Results of the WAIT trial". Colorectal Disease. 19 (11): 973-979. 10.1111/codi.13724.
DOI: https://doi.org/10.1111/codi.13724[23] G. Turri, G. Ostuzzi, G. Vita, and V. Barresi. (2024). "Treatment of locally advanced rectal cancer in the era of total neoadjuvant therapy". JAMA Network Open. 7 (6): e2414702. 10.1001/jamanetworkopen.2024.14702.
DOI: https://doi.org/10.1001/jamanetworkopen.2024.14702[24] C. Aschele and R. Glynne-Jones. (2023). "Selecting a TNT Schedule in Locally Advanced Rectal Cancer: Can We Predict Who Actually Benefits?". Cancers (Basel). 15 (9). 10.3390/cancers15092567.
DOI: https://doi.org/10.3390/cancers15092567[25] M. Erkaya, C. Benlice, B. Baca, and E. Gorgun. (2025). "Survival outcomes and pathologic complete response following neoadjuvant chemoradiotherapy versus chemotherapy alone in locally advanced rectal cancer". Surgical Oncology. 61 : 102252. 10.1016/j.suronc.2025.102252.
DOI: https://doi.org/10.1016/j.suronc.2025.102252[26] W. Zhang, Y. Tang, L. Wei, S. Liu, W. Wang, Y. Chi, Y. Wang, W. Kang, W. Huang, F. Deng, H. Li, H. Ma, L. Jiang, Z. Ding, L. Feng, Y. Li, Y. Chen, H. Zhou, C. Hu, and J. Jin. (2024). "Preoperative short-course radiotherapy followed by chemotherapy and PD-1 inhibitor administration for locally advanced rectal cancer: A study protocol of a randomized phase II/III trial (STELLAR II study)". Colorectal Disease. 26 (9): 1732-1740. 10.1111/codi.17090.
DOI: https://doi.org/10.1111/codi.17090[27] M. Diefenhardt, M. Fleischmann, D. Martin, R. D. Hofheinz, P. Piso, C. T. Germer, P. Hambsch, R. Grutzmann, S. Kirste, A. Schlenska-Lange, M. Ghadimi, C. Rodel, E. Fokas, and G. German Rectal Cancer Study. (2023). "Clinical outcome after total neoadjuvant treatment (CAO/ARO/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO/ARO/AIO-04) a comparison between two multicenter randomized phase II/III trials". Radiotherapy and Oncology. 179 : 109455. 10.1016/j.radonc.2022.109455.
DOI: https://doi.org/10.1016/j.radonc.2022.109455[28] S. Bedrikovetski, L. Traeger, W. Seow, N. N. Dudi-Venkata, S. Selva-Nayagam, M. Penniment, and T. Sammour. (2024). "Oncological Outcomes and Response Rate After Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Network Meta-Analysis Comparing Induction vs. Consolidation Chemotherapy vs. Standard Chemoradiation". Clinical Colorectal Cancer. 23 (4): 326-336 e9. 10.1016/j.clcc.2024.06.001.
DOI: https://doi.org/10.1016/j.clcc.2024.06.001[29] M. Diefenhardt, A. Schlenska-Lange, T. Kuhnt, S. Kirste, P. Piso, W. O. Bechstein, G. Hildebrandt, M. Ghadimi, R. D. Hofheinz, C. Rodel, and E. Fokas. (2022). "Total Neoadjuvant Therapy for Rectal Cancer in the CAO/ARO/AIO-12 Randomized Phase 2 Trial: Early Surrogate Endpoints Revisited". Cancers (Basel). 14 (15). 10.3390/cancers14153658.
DOI: https://doi.org/10.3390/cancers14153658[30] A. Amariyil, S. Pathy, A. Sharma, S. Kumar, R. Pramanik, S. Bhoriwal, and R. M. Pandey. (2024). "Randomized Controlled Trial of Neoadjuvant Short-Course Radiotherapy Followed by Consolidation Chemotherapy Versus Long-Course Chemoradiotherapy in Locally Advanced Rectal Cancer: Comparison of Overall Response Rates". Journal of Gastrointestinal Cancer. 55 (1): 373-382. 10.1007/s12029-023-00966-9.
DOI: https://doi.org/10.1007/s12029-023-00966-9[31] P. J. Nilsson, B. van Etten, G. A. Hospers, L. Pahlman, C. J. van de Velde, R. G. Beets-Tan, L. Blomqvist, J. C. Beukema, E. Kapiteijn, C. A. Marijnen, I. D. Nagtegaal, T. Wiggers, and B. Glimelius. (2013). "Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer--the RAPIDO trial". BMC Cancer. 13 279. 10.1186/1471-2407-13-279.
DOI: https://doi.org/10.1186/1471-2407-13-279[32] S. Liu, T. Jiang, L. Xiao, S. Yang, Q. Liu, Y. Gao, G. Chen, and W. Xiao. (2021). "Total Neoadjuvant Therapy (TNT) versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis". Oncologist. 26 (9): e1555-e1566. 10.1002/onco.13824.
DOI: https://doi.org/10.1002/onco.13824